Hercules, CA — December 5, 2013 — Scientists and journals have been slow to adopt the Minimum Information for the Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines that were established in 2009 to bolster the reliability of real-time PCR (qPCR) and reverse transcription qPCR (RT-qPCR) data. To help boost adoption, Bio-Rad scientists published a brief and practical guide that concisely summarizes the key steps required to produce high-quality, reproducible data for labs conducting RT-qPCR experiments.
“This paper makes a clear and persuasive case for why it is so important to implement the MIQE guidelines by taking each of the major parameters and highlighting the consequences of not implementing quality control procedures,” said Stephen Bustin, one of the scientists who developed the MIQE guidelines.
In the Journal of Molecular Microbiology and Biotechnology article, Bio-Rad’s Sean Taylor and Eli Mrkusich noted that since 2010, only 5% of papers presenting qPCR data have applied the 2009 guidelines. The adoption rate appears to be increasing — a recent MIQE adoption survey in Nature Methods showed a rate of 11% in 2013 — but almost nine out of ten papers published today do not provide the minimum data necessary to be critically evaluated and could therefore include misleading results and conclusions.
“We believe the reason MIQE is not being widely adopted is primarily that techniques used by labs and even by individual lab members are based on teachings from senior scientists or students who have learned from previous labs,” said Taylor. “This has resulted in wide variability in approaches to designing and performing qPCR experiments between and even within labs that have passed from scientist to scientist without critical examination.”
To encourage adoption of the guidelines, Bio-Rad’s new paper uses concrete examples that demonstrate both good and bad practices for RT-qPCR, from experimental design and sample handling to primer validation and reference gene selection. For example, many researchers do not validate their primers because the sequences were sourced from the literature, obtained from other lab members, or from vendors as off-the-shelf assays that may not have been wet-lab validated. This omission is problematic, because the use of unvalidated primers can lead to gene expression data that at best give good results for the target gene and at worst can lead to “incorrect and even opposite conclusions” and sometimes even yield data for the wrong target. The authors detail precisely how primer validation should be performed to avoid these problems.
Bio-Rad has been at the forefront of promoting good PCR practices since 1999 when the company introduced its first qPCR instrument. In 2010, Taylor published an article in the journal Methods outlining the key steps in RT-qPCR data production that “lead to high-quality, reproducible, and publishable data.” More recently Taylor teamed up with researchers at the INRS-Institut Armand-Frappier in Quebec to demonstrate the consequences of choosing the wrong reference gene in the journal Molecular Biotechnology.
The Journal of Molecular Microbiology and Biotechnology article extends Bio-Rad’s commitment to MIQE guidelines.
“This paper continues the exemplary support that Bio-Rad has given, from the very beginning, to the MIQE initiative,” said Bustin. “Bio-Rad has arguably done more than any other real-time PCR company to support, popularize, and help implement MIQE.”
“For the many researchers in highly competitive fields where turnaround time from experiments to publication is critical, this article is a must-read to ensure that the data from this very sensitive assay give results that reflect the true biology of the tested systems,” said Taylor.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,600 people worldwide and had revenues exceeding $2 billion in 2012. Visit us at www.bio‑rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
312-997-2436 x 112